Biohaven Ltd. (BHVN) Stock Forecast & Price Target

Compare

805 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BHVN Analyst Ratings

Moderate Buy

8 Buy

4 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Biohaven

Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BHVN Stock 12 Month Forecast

Average Price Target

$21.30

▲(167.92% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Biohaven Ltd. in the last 3 months. The average price target is $21.30 with a high forecast of $54.00 and a low forecast of $9.00. The average price target represents a 167.92% change from the last price of $7.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","55":"$55","19.75":"$19.75","31.5":"$31.5","43.25":"$43.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,19.75,31.5,43.25,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,20.03076923076923,22.86153846153846,25.69230769230769,28.52307692307692,31.353846153846153,34.184615384615384,37.01538461538461,39.84615384615384,42.676923076923075,45.50769230769231,48.33846153846153,51.169230769230765,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,17.515384615384615,17.83076923076923,18.146153846153847,18.46153846153846,18.776923076923076,19.092307692307692,19.407692307692308,19.723076923076924,20.03846153846154,20.353846153846156,20.66923076923077,20.984615384615385,{"y":21.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,16.569230769230767,15.938461538461539,15.307692307692307,14.676923076923076,14.046153846153846,13.415384615384614,12.784615384615384,12.153846153846153,11.523076923076923,10.892307692307693,10.26153846153846,9.63076923076923,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$21.30

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Samantha Semenkow

Citi

$28→$14

Buy

76.10%

Upside

Reiterated

11/12/25

Strategic Focus and Financial Positioning Drive Buy Rating for Biohaven Ltd.

Myles Minter

William Blair

―

Hold

―

Reiterated

11/10/25

Biohaven Ltd.: Navigating Setbacks with Strategic Restructuring and Promising Pipeline

Leonid Timashev

RBC Capital

Hold

13.21%

Upside

Reiterated

11/10/25

RBC Capital Sticks to Its Hold Rating for Biohaven Ltd. (BHVN)

Jason Gerberry

Bank of America Securities

$10

Hold

25.79%

Upside

Reiterated

11/10/25

Biohaven Ltd. (BHVN) Gets a Hold from Bank of America SecuritiesWe reiterate Neutral and $10 PO.

Tyler Van Buren

TD Cowen

$15

Buy

88.68%

Upside

Reiterated

11/10/25

Strategic Pipeline Focus and Cost Management Drive Buy Rating for Biohaven Ltd.We expect that R&D expenses will get cut in half to preserve runway for these programs. A Type A meeting with the FDA has been requested to appeal the tror/SCA CRL, but investors should consider this program to be in the rear-view mirror.

Douglas Tsao

H.C. Wainwright

$8.26→$30

Buy

277.36%

Upside

Reiterated

11/09/25

H.C. Wainwright Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)

Allison Bratzel

Piper Sandler

$75→$30

Buy

277.36%

Upside

Reiterated

11/06/25

Biohaven price target lowered to $30 from $75 at Piper SandlerBiohaven price target lowered to $30 from $75 at Piper Sandler

William Pickering

Bernstein

$34→$9

Hold

13.21%

Upside

Downgraded

11/06/25

Hold Rating on Biohaven Ltd. Amid Liquidity Challenges and Uncertain Clinical OutcomesWe are downgrading BHVN to $9 PT following Tuesday’s announcement of the CRL for troriluzole in SCA - see our initial reaction here. This is a painful downgrade, as we remain excited about the LT value of the degrader platform, the original reason for our Outperform rating.

Thomas Shrader

BTIG

$33→$16

Buy

101.26%

Upside

Reiterated

11/06/25

BTIG Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Terence Flynn

Morgan Stanley

$54

Buy

579.25%

Upside

Reiterated

11/05/25

Biohaven Ltd.: Strategic Initiatives and Financial Positioning Drive Buy Rating Amid FDA Challenges

Christopher Raymond

Raymond James

―

Buy

―

Reiterated

11/03/25

Optimistic Buy Rating for Biohaven Ltd. Amidst High-Risk PDUFA Decision on TroriluzoleWe think investors would do well to understand some key differences. First, with turmoil at FDA top of mind, we highlight that it is CDER’s Neurology I division reviewing BHVN’s application and CBER interacting with QURE. While the centers do share expertise, there are different patterns for each center. Other differences include the fact that QURE has not yet filed, while BHVN has filed, FDA accepted the file, and assigned priority review. Finally, we note that QURE’s program (gene therapy requiring brain surgery for delivery) is quite a different proposition than an oral prodrug of riluzole (a long-approved treatment for ALS) with a benign safety profile.

Ashwani Verma

UBS

$27→$26

Buy

227.04%

Upside

Reiterated

09/16/25

Biohaven price target lowered to $26 from $27 at UBSBiohaven price target lowered to $26 from $27 at UBS

Marc Goodman

Leerink Partners

$60→$50

Buy

528.93%

Upside

Reiterated

08/12/25

Biohaven price target lowered to $50 from $60 at LeerinkBiohaven price target lowered to $50 from $60 at Leerink

Brian Skorney

Robert W. Baird

$57→$52

Buy

554.09%

Upside

Reiterated

08/12/25

Biohaven price target lowered to $52 from $57 at BairdBiohaven price target lowered to $52 from $57 at Baird

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$54→$30

Buy

277.36%

Upside

Reiterated

08/12/25

Roth MKM Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)we lower our EV/sales multiple from 6.7x to 5x and adjust our PT from $54 to $30

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Samantha Semenkow

Citi

$28→$14

Buy

76.10%

Upside

Reiterated

11/12/25

Strategic Focus and Financial Positioning Drive Buy Rating for Biohaven Ltd.

Myles Minter

William Blair

―

Hold

―

Reiterated

11/10/25

Biohaven Ltd.: Navigating Setbacks with Strategic Restructuring and Promising Pipeline

Leonid Timashev

RBC Capital

Hold

13.21%

Upside

Reiterated

11/10/25

RBC Capital Sticks to Its Hold Rating for Biohaven Ltd. (BHVN)

Jason Gerberry

Bank of America Securities

$10

Hold

25.79%

Upside

Reiterated

11/10/25

Biohaven Ltd. (BHVN) Gets a Hold from Bank of America SecuritiesWe reiterate Neutral and $10 PO.

Tyler Van Buren

TD Cowen

$15

Buy

88.68%

Upside

Reiterated

11/10/25

Douglas Tsao

H.C. Wainwright

$8.26→$30

Buy

277.36%

Upside

Reiterated

11/09/25

H.C. Wainwright Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)

Allison Bratzel

Piper Sandler

$75→$30

Buy

277.36%

Upside

Reiterated

11/06/25

Biohaven price target lowered to $30 from $75 at Piper SandlerBiohaven price target lowered to $30 from $75 at Piper Sandler

William Pickering

Bernstein

$34→$9

Hold

13.21%

Upside

Downgraded

11/06/25

Thomas Shrader

BTIG

$33→$16

Buy

101.26%

Upside

Reiterated

11/06/25

BTIG Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Terence Flynn

Morgan Stanley

$54

Buy

579.25%

Upside

Reiterated

11/05/25

Biohaven Ltd.: Strategic Initiatives and Financial Positioning Drive Buy Rating Amid FDA Challenges

Christopher Raymond

Raymond James

―

Buy

―

Reiterated

11/03/25

Ashwani Verma

UBS

$27→$26

Buy

227.04%

Upside

Reiterated

09/16/25

Biohaven price target lowered to $26 from $27 at UBSBiohaven price target lowered to $26 from $27 at UBS

Marc Goodman

Leerink Partners

$60→$50

Buy

528.93%

Upside

Reiterated

08/12/25

Biohaven price target lowered to $50 from $60 at LeerinkBiohaven price target lowered to $50 from $60 at Leerink

Brian Skorney

Robert W. Baird

$57→$52

Buy

554.09%

Upside

Reiterated

08/12/25

Biohaven price target lowered to $52 from $57 at BairdBiohaven price target lowered to $52 from $57 at Baird

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$54→$30

Buy

277.36%

Upside

Reiterated

08/12/25

Roth MKM Sticks to Its Buy Rating for Biohaven Ltd. (BHVN)we lower our EV/sales multiple from 6.7x to 5x and adjust our PT from $54 to $30

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biohaven Ltd.

1 Month

xxx

Success Rate

9/14 ratings generated profit

Average Return

+8.97%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.29% of your transactions generating a profit, with an average return of +8.97% per trade.

3 Months

xxx

Success Rate

11/21 ratings generated profit

Average Return

+8.64%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.38% of your transactions generating a profit, with an average return of +8.64% per trade.

1 Year

Thomas ShraderBTIG

Success Rate

11/21 ratings generated profit

Average Return

+26.75%

reiterated a buy rating 8 days ago

Copying Thomas Shrader's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +26.75% per trade.

2 Years

xxx

Success Rate

4/14 ratings generated profit

Average Return

-0.84%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -0.84% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BHVN Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BHVN has received 15 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BHVN average Analyst price target in the past 3 months is 21.30.

Each month's total comprises the sum of three months' worth of ratings.

BHVN Financial Forecast

BHVN Earnings Forecast

Next quarter’s earnings estimate for BHVN is -$1.54 with a range of -$2.35 to -$0.33. The previous quarter’s EPS was -$1.64. BHVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

No data currently available

BHVN Sales Forecast

Next quarter’s sales forecast for BHVN is $364.00K with a range of $0.00 to $4.00M. The previous quarter’s sales results were $0.00. BHVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BHVN has Performed in-line its overall industry.

BHVN Stock Forecast FAQ

What is BHVN’s average 12-month price target, according to analysts?

Based on analyst ratings, Biohaven Ltd.’s 12-month average price target is 21.30.

What is BHVN’s upside potential, based on the analysts’ average price target?

Biohaven Ltd. has 167.92% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BHVN a Buy, Sell or Hold?

Biohaven Ltd. has a consensus rating of Moderate Buy which is based on 8 buy ratings, 4 hold ratings and 0 sell ratings.

What is Biohaven Ltd.’s price target?

The average price target for Biohaven Ltd. is 21.30. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $9.00. The average price target represents 167.92% Increase from the current price of $7.95.

What do analysts say about Biohaven Ltd.?

Biohaven Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BHVN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Biohaven Ltd. (BHVN) Stock Forecast & Price Target

BHVN Analyst Ratings

BHVN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biohaven Ltd.

BHVN Analyst Recommendation Trends

BHVN Financial Forecast

BHVN Earnings Forecast

BHVN Sales Forecast

BHVN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts